Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU2ZVY)

• Drug Name: SR12813 Drug Info
• Synonyms: SR 12813; 126411-39-0; SR-12813; SR12813; CHEBI:77317; GW 485801; CHEMBL458767; [2-(3,5-DI-TERT-BUTYL-4-HYDROXY-PHENYL)-1-(DIETHOXY-PHOSPHORYL)-VINYL]-PHOSPHONIC ACID DIETHLYL ESTER; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol; Tetraethyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethenyl-1,1-bisphosphonate; tetraethyl [2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethene-1,1-diyl]bis(phosphonate); [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; SRL; 1ilh; AC1L9JHO

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 446313
  ChEBI ID: CHEBI:77317
  CAS Number: CAS 126411-39-0
  TTD Drug ID: DMU2ZVY

Molecule-Related Drug Atlas

Drug(s) Targeting HMG-CoA reductase (HMGCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[6]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[7]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[8]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[9]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[10]
Fluvastatin	DM4MDJY	Arteriosclerosis	BD40	Approved	[7]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[11]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[7]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[12]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[11]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[13]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[15]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[16]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[17]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[18]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[19]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[20]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[21]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[22]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[23]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[24]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[25]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[26]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[27]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[28]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[29]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[30]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[28]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 2 (NR1I2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[31]
Vidarabine	DM0N85H	Hepatosplenic T-cell lymphoma		Approved	[31]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[32]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[33]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[34]
Etidronic acid	DM1XHYJ	Bone Paget disease		Approved	[31]
Tiaprofenic acid	DM23D7J	Osteoarthritis	FA00-FA05	Approved	[31]
Bromperidol	DM24XYQ	Schizophrenia	6A20	Approved	[31]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[35]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[36]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[3]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[4]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2763).
• [2] The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A r... J Biol Chem. 1996 Jun 14;271(24):14376-82.
• [3] Regulation of drug resistance by human pregnane X receptor in breast cancer. Cancer Biol Ther. 2009 Jul;8(13):1265-72.
• [4] Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol Sci. 2006 Jun;91(2):501-9.
• [5] Pregnane X receptor PXR activates the GADD45beta gene, eliciting the p38 MAPK signal and cell migration. J Biol Chem. 2011 Feb 4;286(5):3570-8. doi: 10.1074/jbc.M110.179812. Epub 2010 Dec 2.
• [6] A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
• [7] Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
• [8] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [9] Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
• [10] New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
• [11] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [12] Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
• [13] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [14] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [15] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [16] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [17] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [18] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [19] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [20] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [21] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [22] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [23] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [24] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [25] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [26] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [27] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [28] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [29] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [30] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [31] Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
• [32] Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta. 2005 May 30;1740(2):162-9. doi: 10.1016/j.bbadis.2004.11.013. Epub 2004 Dec 8.
• [33] Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33. doi: 10.1016/j.taap.2005.03.015.
• [34] Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
• [35] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [36] Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017 Jan 4;265:86-96.